What is Sosei Group Corporation?
operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally.
SOLTF · Verdict
Solid reward · elevated risk
SOLTF stands out on growth and volatility, but watch the cash flow signal.
Based on 88% data coverage
SOLTF · Verdict
Revenue +23.9% CAGR
Above average
-11% free-cash-flow margin
Current ratio 2.54
-42% net margin · -19% ROE
Below average
Model-based scoring. For information only — not financial advice.
operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 497.04M.
The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.